Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies - Obligations for Each Relevant Transaction (Details)

v3.23.1
Summary of Significant Accounting Policies - Obligations for Each Relevant Transaction (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Business Acquisition [Line Items]    
Fair value of contingent consideration $ 322,385 $ 0
Bayon acquisition | Successful completion of Phase 1b $0.495 million    
Business Acquisition [Line Items]    
Fair value of contingent consideration 500,000  
Bayon acquisition | Successful completion of Phase 2 $0.990 million    
Business Acquisition [Line Items]    
Fair value of contingent consideration 1,000,000.0  
Bayon acquisition | Successful completion of Phase 3 $4 million    
Business Acquisition [Line Items]    
Fair value of contingent consideration 4,000,000.0  
Bayon acquisition | FDA approval    
Business Acquisition [Line Items]    
Fair value of contingent consideration 1,700,000  
Panoptes acquisition | FDA approval    
Business Acquisition [Line Items]    
Fair value of contingent consideration 4,800,000  
Panoptes acquisition | Beginning of Phase 3    
Business Acquisition [Line Items]    
Fair value of contingent consideration 4,800,000  
Jade acquisition | FDA approval    
Business Acquisition [Line Items]    
Fair value of contingent consideration $ 2,200,000